Ratings Geron Corporation

Equities

GERN

US3741631036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.58 ^USD	+2.29%		0.00%	+69.67%

Mar. 19	Geron Prices $150 Million Offering of Shares, Pre-Funded Warrants	MT
Mar. 15	Sector Update: Health Care Stocks Ease Late Afternoon	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
GERON CORPORATION	+69.67%	2.06B	C+
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B	B+
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B	B+
ARGENX SE	+1.86%	22.19B	B
BIONTECH SE	-16.53%	21.33B	B+
GENMAB A/S	-8.49%	18.68B	A-
WUXI APPTEC CO., LTD.	-42.33%	16.6B	A-
BEIGENE, LTD.	-20.09%	14.52B	B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B	C+
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes